Literature DB >> 26153146

iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer?

Christina Bluemel1, Andreas Cramer2, Christoph Grossmann2, Georg W Kajdi3, Uwe Malzahn4, Nora Lamp5, Heinz-Jakob Langen6, Jan Schmid3, Andreas K Buck3, Hanns-Jörg Grimminger2, Ken Herrmann3.   

Abstract

PURPOSE: To prospectively evaluate the feasibility of 3-D radioguided occult lesion localization (iROLL) and to compare iROLL with wire-guided localization (WGL) in patients with early-stage breast cancer undergoing breast-conserving surgery and sentinel lymph node biopsy (SLNB).
METHODS: WGL (standard procedure) and iROLL in combination with SLNB were performed in 31 women (mean age 65.1 ± 11.2 years) with early-stage breast cancer and clinically negative axillae. Patient comfort in respect of both methods was assessed using a ten point scale. SLNB and iROLL were guided by freehand SPECT (fhSPECT). The results of the novel 3-D image-based method were compared with those of WGL, ultrasound-based lesion localization, and histopathology.
RESULTS: iROLL successfully detected the malignant primary and at least one sentinel lymph node in 97% of patients. In a single patient (3%), only iROLL, and not WGL, enabled lesion localization. The variability between fhSPECT and ultrasound-based depth localization of breast lesions was low (1.2 ± 1.4 mm). Clear margins were achieved in 81% of the patients; however, precise prediction of clear histopathological surgical margins was not feasible using iROLL. Patients rated iROLL as less painful than WGL with a pain score 0.8 ± 1.2 points (p < 0.01) lower than the score for iROLL.
CONCLUSION: iROLL is a well-tolerated and feasible technique for localizing early-stage breast cancer in the course of breast-conserving surgery, and is a suitable replacement for WGL. As a single image-based procedure for localization of breast lesions and sentinel nodes, iROLL may improve the entire surgical procedure. However, no advantages of the image-guided procedure were found with regard to prediction of complete tumour resection.

Entities:  

Mesh:

Year:  2015        PMID: 26153146     DOI: 10.1007/s00259-015-3121-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  29 in total

Review 1.  Strategies for localisation of impalpable breast lesions.

Authors:  Sascha Miles Dua; Richard J Gray; Mohammed Keshtgar
Journal:  Breast       Date:  2011-02-01       Impact factor: 4.380

2.  Radioguided occult lesion localisation in breast cancer using an intraoperative portable gamma camera: first results.

Authors:  P Paredes; S Vidal-Sicart; G Zanón; N Roé; S Rubí; S Lafuente; J Pavía; F Pons
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-28       Impact factor: 9.236

3.  Freehand SPECT for image-guided sentinel lymph node biopsy in breast cancer.

Authors:  Christina Bluemel; Andreas Schnelzer; Asli Okur; Alexandra Ehlerding; Stefan Paepke; Klemens Scheidhauer; Marion Kiechle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-11       Impact factor: 9.236

4.  Radioguided surgery of occult breast lesions.

Authors:  A Luini; S Zurrida; V Galimberti; G Paganelli
Journal:  Eur J Cancer       Date:  1998-01       Impact factor: 9.162

5.  Efficacy of 'radioguided occult lesion localisation' (ROLL) versus 'wire-guided localisation' (WGL) in breast conserving surgery for non-palpable breast cancer: a randomised controlled multicentre trial.

Authors:  E L Postma; H M Verkooijen; S van Esser; M G Hobbelink; G P van der Schelling; R Koelemij; A J Witkamp; C Contant; P J van Diest; S M Willems; I H M Borel Rinkes; M A A J van den Bosch; W P Mali; R van Hillegersberg
Journal:  Breast Cancer Res Treat       Date:  2012-09-30       Impact factor: 4.872

6.  Response to comment by Aprile et al.: the EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.

Authors:  F Giammarile; N Alazraki; J N Aarsvold; R A Audisio; E Glass; S F Grant; J Kunikowska; M Leidenius; V M Moncayo; R F Uren; W J Oyen; R A Valdés Olmos; S Vidal Sicart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-26       Impact factor: 9.236

7.  Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.

Authors:  R Kreienberg; U-S Albert; M Follmann; I B Kopp; T Kühn; A Wöckel
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-06       Impact factor: 2.915

8.  Radioguided localization of nonpalpable breast cancer lesions: randomized comparison with wire localization in patients undergoing conservative surgery and sentinel node biopsy.

Authors:  Antonio Mariscal Martínez; Montse Solà; Anna Pérez de Tudela; Juan Francisco Julián; Manuel Fraile; Sara Vizcaya; Jaume Fernández
Journal:  AJR Am J Roentgenol       Date:  2009-10       Impact factor: 3.959

9.  High-resolution, handheld camera use for occult breast lesion localization plus sentinel node biopsy (SNOLL): a single-institution experience with 186 patients.

Authors:  Augusto Lombardi; Giuseppe Nigri; Francesco Scopinaro; Stefano Maggi; Mauro Mattei; Adriana Bonifacino; Maria Parisella; Alessandro Soluri; Claudio Amanti
Journal:  Surgeon       Date:  2013-11-21       Impact factor: 2.392

10.  Magnetic resonance imaging-radioguided occult lesion localization (ROLL) in breast cancer using Tc-99m macro-aggregated albumin and distilled water control.

Authors:  Fernanda Philadelpho Arantes Pereira; Gabriela Martins; Maria Julia Gregorio Calas; Maria Veronica Fonseca Torres de Oliveira; Emerson Leandro Gasparetto; Lea Mirian Barbosa da Fonseca
Journal:  BMC Med Imaging       Date:  2013-09-18       Impact factor: 1.930

View more
  1 in total

1.  Fusion of freehand SPECT and ultrasound: First experience in preoperative localization of sentinel lymph nodes.

Authors:  Christina Bluemel; Gonca Safak; Andreas Cramer; Achim Wöckel; Anja Gesierich; Elena Hartmann; Jan-Stefan Schmid; Franz Kaiser; Andreas K Buck; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-17       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.